Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 6/20 | 0.33 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19634614 | 0.95 | HTT (0.40) | HTTKCNN4KCNA5LMNALTB4R | |
| SCHEMBL19634601 | 0.89 | HTT (0.44) | HTTKCNN4KCNA5LMNAHIF1A | |
| SCHEMBL8987951 | 0.77 | MEN1 (0.41) | LMNAL3MBTL1 | |
| SCHEMBL18104688 | 0.76 | CYP3A4 (0.37) | HTTLMNAL3MBTL1TSHR | |
| SCHEMBL8756382 | 0.76 | EPHX2 (0.41) | CNR2TSHR | |
| SCHEMBL11711810 | 0.76 | EPHX2 (0.41) | CNR2TSHR | |
| SCHEMBL4934443 | 0.76 | EPHX2 (0.41) | CNR2TSHR | |
| SCHEMBL8403328 | 0.76 | ALDH1A1 (0.37) | HTTLMNAL3MBTL1TSHR | |
| SCHEMBL8882499 | 0.75 | HTT (0.45) | HTTLMNAHIF1AL3MBTL1TSHR | |
| SCHEMBL4821584 | 0.75 | MEN1 (0.42) | HTTL3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3831841-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T Global Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| US-20190151403-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. | 2019-05-23 | — | — | US | disclosed |
| WO-2017200984-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. (US) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151403-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | MALT1, MYLK2, FKBP1B | HTT 1394/4885KCNN4 4198/4885KCNA5 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.